by Nicolas Hulscher, MPH

The global expansion of high-containment biolabs without oversight — increasingly engaged in Nipah virus research — combined with aggressive patent consolidation of Nipah's core glycoproteins and their integration into mRNA and self-amplifying mRNA (saRNA) injection platforms, represents a profound and escalating global biosecurity risk.

A recent study identified 3,625 Biosafety Level-3 and Level-4 laboratories worldwide:

• 73% do not publicly disclose their locations or pathogen activities

• 91% of countries operating BSL-3 labs lack dual-use research oversight

• Roughly half of global facilities are located in the United States

• More than 300 documented lab leaks have occurred since 2001.